20-Mar-2026
Guggenheim Keeps Their Buy Rating on Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks (Fri, 20-Mar 7:36 AM ET)
Globe Newswire (Wed, 11-Mar 7:30 AM ET)
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Globe Newswire (Wed, 25-Feb 7:00 AM ET)
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Globe Newswire (Thu, 5-Feb 7:00 AM ET)
Market Chameleon (Tue, 3-Feb 6:08 AM ET)
Globe Newswire (Mon, 2-Feb 7:00 AM ET)
Market Chameleon (Thu, 29-Jan 2:07 AM ET)
PRNewswire (Thu, 29-Jan 6:00 AM ET)
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
Globe Newswire (Tue, 27-Jan 3:00 AM ET)
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Globe Newswire (Thu, 8-Jan 7:00 AM ET)
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.
As of March 20, 2026, SGMT stock price declined to $4.82 with 358,439 million shares trading.
SGMT has a beta of 3.61, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.30 to the broad based SPY ETF.
SGMT has a market cap of $157.06 million. This is considered a Micro Cap stock.
Last quarter Sagimet Biosciences - Series A reported $0 in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.12.
The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, VXF, IBB, IWC, DFAS.
SGMT has outperformed the market in the last year with a return of +19.0%, while the SPY ETF gained +16.6%. However, in the most recent history, SGMT shares have underperformed the stock market with its stock returning -23.2% in the last 3 month period and -10.9% for the last 2 week period, while SPY has returned -4.4% and -3.3%, respectively.
SGMT support price is $4.61 and resistance is $5.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.